←
David Yang59 posts
David Yang avatar

David Yang

@DYangMD

Radiation Oncologist at @DanaFarber @BrighamWomens @harvardmed and Research Fellow in @VanAllenLab. All views are my own.

◷ Joined December 2009▧ 2 Photos and videos
David Yang avatar
David Yang@DYangMD·Aug 19

Many thanks to @ACSNews and @SpeedofLightFdn as well as my mentors and collaborators for all your support! @VanAllenLab @DrPaulNguyen @MtkingMD

Congratulations to the winner of the 2026 ASTRO-ACS Clinician Scientist Development Grant: David D. Yang, MD, researching “Advancing Biomarker Discovery in Prostate Cancer Through Computer Vision-Driven Profiling of Tumor and Microenvironmental Heterogeneity” Learn more: bit.ly/4g07pN1 @AmericanCancer @DYangMD @DanaFarber

Post attachment
David Yang avatar
David Yang@DYangMD·May 19

Deeply grateful to my coauthors, the patients and loved ones who made this work possible, and @PCFnews for supporting this study 7/n

David Yang avatar
David Yang@DYangMD·May 19

Together, our findings nominate immune spatial clustering as a potential biomarker of clinically meaningful immune enrichment in high-grade localized prostate cancer 6/n

David Yang avatar
David Yang@DYangMD·May 19

These immune clusters were also associated with molecular features suggestive of a T cell-mediated antitumor response 5/n

David Yang avatar
David Yang@DYangMD·May 19

We found that immune cell quantity alone was not associated with outcomes. Instead, a higher burden of spatially dense immune clusters was associated with a lower risk of distant metastasis in two independent cohorts 4/n

David Yang avatar
David Yang@DYangMD·May 19

We leveraged deep learning analysis of H&E images (obtained as part of routine care) to evaluate whether immune features were associated with outcomes after prostatectomy 3/n

David Yang avatar
David Yang@DYangMD·May 19

Growing evidence suggests that a subset of prostate cancer is immune-enriched, but the clinical consequences of immune enrichment were largely unknown 2/n

David Yang avatar
David Yang@DYangMD·May 19

Excited to share our work on immune microenvironmental features in prostate cancer!

In our latest, a surprise - thanks to computational pathology - about immune cell clustering in prostate cancer and new ways to understand tumors, their neighborhoods, and clinical outcomes ... congrats @DYangMD et al! (link below)

Post attachment
Josh Lang avatar
⟳ David Yang retweeted
Josh Lang@JoshLangMD·11 Dec 2024

Tonight we sit with the cherished memories of a truly unforgettable individual who changed the lives of so many fighting cancer. Tomorrow we stand and get back to the fight against the terrible disease that took one of our best, brightest, and kindest. Love you forever, Felix.

David Yang avatar
David Yang@DYangMD·3 Nov 2024

If further validated, AI-determined tumor volume may become a novel biomarker for improving risk stratification for pts w/ localized PCa (in addition to genomics and computational pathology approaches) 7/n

David Yang avatar
David Yang@DYangMD·3 Nov 2024

The AI-determined tumor volume may also have greater performance for predicting MFS than NCCN risk groups (e.g. AUROC for 7y MFS 0.84 vs 0.74, p=0.02 for RT-treated patients) 6/n

David Yang avatar
David Yang@DYangMD·3 Nov 2024

Particularly interesting was our observation the intraprostatic tumor size was associated with both BCR and MFS for both RT and RP-treated patients, even after adjusting for the clinical, radiologic, and pathologic characteristics 5/n

David Yang avatar
David Yang@DYangMD·3 Nov 2024

Using a cohort of 732 patients w/ PCa and mpMRIs, we built a segmentation model with the nnU-Net approach which showed good performance (e.g. F1 scores of 84-87% for PI-RADS 3-5 lesions across training/test cohorts) 4/n

David Yang avatar
David Yang@DYangMD·3 Nov 2024

We envisioned that this model would be useful in several ways, such as for focal microboosts for EBRT: redjournal.org/article/S0360… 3/n